Skip to main content
    S

    Standard Biotools Inc (LAB)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.62
    -0.09 (-12.21%)

    Market Cap: $279.27M

    Last updated: Nov 17, 2026 at 11:02 AM ET

    Standard Biotools Inc (LAB) Financials: Revenue, Profit and Cash Flow

    Updated Nov 3, 2026. Financial statements from company filings, amounts in US dollars.

    Standard Biotools reported revenue of $85.33M for the fiscal year ended Dec 31, 2025, down 6.2% from the year before. That year, net income was -$74.90M with a net margin of -87.8%, operating cash flow was -$74.34M and free cash flow was -$82.65M. The quarter ended Sep 30, 2026 had revenue of $19.39M and net income of $13.48M.

    Revenue and Margins

    The net margin was -87.8% in the fiscal year ended Dec 2025, the lowest of the 8 years shown with a net margin. Over the 9 years to Dec 2025, revenue fell from $193.45M, a compound annual decline of 8.7%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$85.33M-6.2%49.9%-129.2%-87.8%
    Dec 2024$91.01M-14.4%49.3%-140.1%-152.6%
    Dec 2023$106.34M+8.6%47.4%-72.0%-70.2%
    Dec 2022$97.95M-25.0%37.8%-118.6%-194.1%
    Dec 2021$130.58M-5.5%53.1%-51.7%-45.4%
    Dec 2020$138.14M+17.8%60.3%-36.9%-38.4%
    Dec 2019$117.24M+3.8%54.8%-44.2%-55.3%
    Dec 2018$112.96M-39.4%54.6%-42.6%-52.2%
    Dec 2017$186.34M-3.7%27.9%-31.3%-32.5%
    Dec 2016$193.45MN/A30.2%-37.8%-39.3%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$85.33M$91.01M$106.34M$97.95M$130.58M$138.14M$117.24M$112.96M$186.34M$193.45M
    Cost of revenue$42.79M$46.13M$55.89M$60.90M$61.21M$54.82M$52.96M$51.31M-$34.44M-$42.99M
    Gross profit$42.54M$44.88M$50.45M$37.05M$69.37M$83.33M$64.28M$61.65M$51.98M$58.44M
    Research and development$25.99M$28.83M$25.95M$37.38M$37.94M$36.46M$31.64M$30.03M$30.83M$38.41M
    Operating income-$110.25M-$127.48M-$76.60M-$116.20M-$67.46M-$51.04M-$51.84M-$48.16M-$58.36M-$73.19M
    Net income-$74.90M-$138.88M-$74.66M-$190.10M-$59.24M-$53.02M-$64.79M-$59.01M-$60.53M-$75.98M
    EBITDA-$97.52M-$97.85M-$61.29MN/A-$43.64M-$32.04M-$33.18M-$22.58M-$39.08M-$56.14M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$19.39M$20.10M$21.15M$3.22M$19.55M$21.76M$20.22M$890.00K$22.09M$22.49M$45.54M$28.19M
    Gross profit$10.83M$10.54M$11.31M$2.69M$9.48M$10.63M$11.05M-$1.80M$12.13M$10.37M$24.19M$13.41M
    Operating income-$19.77M-$25.39M-$12.50M-$18.64M-$32.94M-$25.70M-$26.97M-$10.34M-$26.70M-$30.26M-$60.18M-$21.39M
    Net income$13.48M-$26.76M$127.07M$19.28M-$34.69M-$33.46M-$26.03M-$34.07M-$26.94M-$45.72M-$32.16M-$19.78M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $5.79M by $115.07M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$567.75M$612.35M$323.07M$390.31M$275.21M$324.76M$264.81M$303.65M$287.35M$306.39M
    Current assets$454.26M$375.88M$158.22M$208.81M$72.07M$117.66M$96.10M$127.11M$94.80M$96.67M
    Cash and equivalents$120.86M$166.73M$51.70M$81.31M$28.45M$68.52M$21.66M$95.40M$58.06M$35.05M
    Total liabilities$143.46M$140.62M$159.87M$160.52M$180.62M$185.71M$111.20M$231.53M$256.42M$253.16M
    Short-term debt$5.49M$6.23M$59.53M$2.08M$6.84M$0$1.83M$0$0$0
    Long-term debt$299.00K$299.00K$3.98M$62.81M$64.21M$54.22M$53.82M$172.06M$195.24M$194.95M
    Shareholder equity$424.29M$471.72M-$148.05M-$81.47M$94.60M$139.05M$153.61M$72.12M$30.93M$53.23M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$635.33M$627.22M$639.11M$567.75M$539.64M$556.97M$579.60M$612.34M$681.54M$708.73M$777.67M$323.07M
    Total liabilities$79.58M$87.25M$77.99M$143.46M$139.98M$132.43M$125.00M$140.62M$192.21M$198.47M$200.35M$159.87M
    Cash and equivalents$267.49M$270.03M$265.77M$118.21M$129.42M$158.62M$150.88M$166.73M$210.65M$269.81M$287.06M$51.70M
    Shareholder equity$555.75M$539.97M$561.12M$424.29M$399.66M$424.54M$454.60M$471.72M$489.33M$510.26M$577.32M$163.20M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$74.34M-$143.45M-$43.29M-$89.37M-$44.06M-$15.42M-$35.21M-$25.20M-$24.10M-$39.14M
    Capital expenditures$8.30M$8.36M$2.83M$3.83M$13.26M$12.72M$2.53M$372.00K$1.57M$5.07M
    Free cash flow-$82.65M-$151.81M-$46.12M-$93.19M-$57.33M-$28.13M-$37.74M-$25.57M-$25.66M-$44.20M
    Dividends paidN/AN/AN/AN/A$299.00KN/A$1.50MN/AN/AN/A
    Share repurchases$0$40.49M$5.41M$13.11M$79.00K$684.00K$1.89M$2.86M$0N/A
    Investing cash flow$27.41M$363.17M$20.24M-$88.13M-$11.95M$39.98M-$39.30M$4.72M$17.66M$45.10M
    Financing cash flow$570.00K-$102.62M-$6.81M$230.76M$15.96M$20.86M$2.79M$57.66M$29.00M$116.00K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$6.16M-$10.31M-$46.60M-$1.19M-$22.20M-$20.67M-$30.28M-$14.06M-$27.87M-$39.05M-$62.48M-$14.06M
    Capital expendituresN/A$344.00K$570.00K$476.00K$886.00K$1.89M$5.05M$3.38M$2.25M$1.94M$781.00K$78.00K
    Free cash flowN/A-$10.65M-$47.17M-$1.67M-$23.09M-$22.55M-$35.34M-$17.44M-$30.12M-$40.99M-$63.26M-$14.14M
    Last 12 quarters

    Frequently Asked Questions About LAB

    What is Standard Biotools' annual revenue?

    Standard Biotools reported revenue of $85.33M for the fiscal year ended Dec 31, 2025.

    How fast is Standard Biotools' revenue growing?

    Revenue was down 6.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -4.5%.

    Is Standard Biotools profitable?

    No. Standard Biotools reported net income of -$74.90M for the fiscal year ended Dec 31, 2025, with a net margin of -87.8%.

    How much free cash flow does LAB generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$74.34M minus capital expenditures of $8.30M produced free cash flow of -$82.65M.

    How much debt does Standard Biotools have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $299.00K, short-term debt of $5.49M and cash and equivalents of $120.86M.